Follow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young Children


Trial ID: NCT03859700


Open-label, follow-up study for subjects who completed the EPITOPE study.

Official Title

EPITOPE Open-label Extension Study to Evaluate the Long-term Clinical Benefit and Safety of DBV712 in Peanut-Allergic Children

Stanford Investigator(s)

Sayantani Sindher

Clinical Associate Professor, Medicine Clinical Associate Professor, Pediatrics - Allergy and Clinical Immunology


Inclusion Criteria:

   - completion of the EPITOPE study

Exclusion Criteria:

   - Generalized dermatologic disease (for example, active atopic dermatitis, uncontrolled
   generalized active eczema, ichthyosis vulgaris) extending widely on the skin and
   especially on the back or arms with no intact zones to apply the Viaskin patches.

   - Diagnosis of asthma that evolved to severe, unstable or uncontrolled asthma


biological: DBV712 250 mcg


Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305